Cut-price CAR-T cell therapies top India’s biotech agenda

Indian startups plan affordable CAR-T therapies—first for domestic use, then for the global market.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Killugudi Jayaraman.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jayaraman, K. Cut-price CAR-T cell therapies top India’s biotech agenda. Nat Biotechnol 37, 1388–1389 (2019). https://doi.org/10.1038/s41587-019-0346-1

Download citation